Price Alert

Dyne Therapeutics Inc. (DYN)

NASDAQ: DYN · Real-Time Price · USD

12.24

-0.09 (-0.73%)

At close: Aug 19, 2025, 3:59 PM

12.25

0.04%

After-hours: Aug 19, 2025, 04:32 PM EDT

-0.73% (1D)

Bid	12
Market Cap	1.74B
Revenue (ttm)	n/a
Net Income (ttm)	-412.88M
EPS (ttm)	-3.88
PE Ratio (ttm)	-3.16
Forward PE	-3.17
Analyst	Buy

Ask	13.33
Volume	1,237,493
Avg. Volume (20D)	2,918,533
Open	12.31
Previous Close	12.33
Day's Range	12.05 - 12.42
52-Week Range	6.36 - 47.45
Beta	1.08

About DYN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DYN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DYN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

+7.72%

Dyne Therapeutics shares are trading higher on pos... Unlock content with Pro Subscription

1 month ago

-8.82%

Dyne Therapeutics shares are trading lower after the company announced a $200 million public offering.

News

2 weeks ago · zacks.com

Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?

The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon...

3 weeks ago · benzinga.com

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Dyne Therapeutics Inc DYN reported a loss for the second quarter on Monday.

3 weeks ago · fool.com

Dyne Reports Wider Loss in Fiscal Q2

1 month ago · businesswire.com

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatm...

1 month ago · benzinga.com

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.

2 months ago · seekingalpha.com

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical appr...

2 months ago · businesswire.com

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

LOS ANGELES--(BUSINESS WIRE)---- $DYN--Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN.